CNS Pharmaceuticals (NASDAQ:CNSP) Issues Earnings Results, Misses Estimates By $0.14 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) issued its quarterly earnings data on Wednesday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14), FiscalAI reports.

CNS Pharmaceuticals Stock Up 1.0%

Shares of CNSP traded up $0.05 during mid-day trading on Friday, reaching $5.20. The company’s stock had a trading volume of 4,628 shares, compared to its average volume of 7,347. The company has a market cap of $7.59 million, a price-to-earnings ratio of -0.22 and a beta of 3.05. The business has a fifty day moving average of $4.95 and a 200 day moving average of $4.17. CNS Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $10.59.

Insiders Place Their Bets

In other CNS Pharmaceuticals news, Director Faith L. Charles acquired 7,100 shares of CNS Pharmaceuticals stock in a transaction that occurred on Monday, May 18th. The stock was purchased at an average cost of $4.79 per share, with a total value of $34,009.00. Following the purchase, the director owned 7,100 shares in the company, valued at approximately $34,009. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.01% of the company’s stock.

Institutional Trading of CNS Pharmaceuticals

Several institutional investors have recently made changes to their positions in CNSP. Boothbay Fund Management LLC purchased a new position in CNS Pharmaceuticals during the fourth quarter valued at approximately $71,000. Ikarian Capital LLC acquired a new stake in shares of CNS Pharmaceuticals during the 4th quarter valued at about $241,000. Finally, Armistice Capital LLC bought a new stake in shares of CNS Pharmaceuticals in the 2nd quarter valued at approximately $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.